Compare Levi Strauss & Co. (LEVI) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Tenet Healthcare Corporation — how do they compare? Levi Strauss & Co. trades at $18.69 (market cap $7.31B), while Tenet Healthcare Corporation trades at $265.57 (market cap $20.98B). The key difference: Tenet Healthcare Corporation is far larger — about 2.9× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays a 3.36% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and Tenet Healthcare Corporation for 15 Days on average.
| LEVI | THC | |
|---|---|---|
Market Cap | $7.31B | $20.98B |
Volume | 13,683,095 | 428,008 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $280.77 |
52-Week Low | $17.92 | $161.37 |
Typical Hold Time | 70 Days | 15 Days |
Enterprise Value | $8.86B | $32.06B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $18.71, down 4.13% today, with a bearish technical outlook despite strong fundamentals. The company has beaten earnings estimates for four consecutive quarters, maintains a healthy gross margin of 62.81%, and shows improving cash flow trends. Analyst consensus remains strongly bullish with a $29.00 price target, representing 55% upside potential from current levels.
The stock presents a compelling value opportunity with a P/E of 12.5x and strong brand momentum, though technical weakness and recent cybersecurity incidents pose near-term risks. Wall Street's overwhelming buy rating (79%) suggests confidence in Levi's direct-to-consumer strategy and international expansion driving future growth.
Tenet Healthcare (THC) trades at $265.42, up 2.15% today, with a bullish technical signal from moving averages and strong support near $257. The company shows robust fundamentals, including a 53.31% ROE and consistent earnings beats, with Q3 2026 results due October 29. Revenue growth is supported by higher revenue per case despite softer surgical volumes, as noted by Zacks on September 24, 2026.
The outlook is positive, with an 81.25% analyst buy rating and a $283.36 consensus price target implying ~7% upside. Risks include sustainability of capital returns amid growth investments and potential volume pressures, but solid cash flow and valuation metrics like a 10.07 P/E suggest room for appreciation if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
